Phase I study of TAS-121, a third-generation epidermal growth factor receptor (EGFR) tyrosine kinase inhibitor, in patients with non-small-cell lung cancer harboring EGFR mutations

[1]  E. Tan,et al.  Management of epidermal growth factor receptor tyrosine kinase inhibitor‐related cutaneous and gastrointestinal toxicities , 2018, Asia-Pacific journal of clinical oncology.

[2]  Edward S. Kim,et al.  Efficacy and Safety Results of the Afatinib Expanded Access Program , 2017, Oncology and Therapy.

[3]  M. Ahn,et al.  Osimertinib or Platinum–Pemetrexed in EGFR T790M–Positive Lung Cancer , 2017, The New England journal of medicine.

[4]  C. Paweletz,et al.  Association Between Plasma Genotyping and Outcomes of Treatment With Osimertinib (AZD9291) in Advanced Non-Small-Cell Lung Cancer. , 2016, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  F. Ciardiello,et al.  Mechanisms of resistance to EGFR-targeted drugs: lung cancer , 2016, ESMO Open.

[6]  S. Digumarthy,et al.  Osimertinib Responses After Disease Progression in Patients Who Had Been Receiving Rociletinib. , 2016, JAMA oncology.

[7]  Dong-Wan Kim,et al.  Mechanisms of Acquired Resistance to AZD9291: A Mutation-Selective, Irreversible EGFR Inhibitor , 2015, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

[8]  D. Planchard,et al.  EGFR-independent mechanisms of acquired resistance to AZD9291 in EGFR T790M-positive NSCLC patients. , 2015, Annals of oncology : official journal of the European Society for Medical Oncology.

[9]  Aleksandra Markovets,et al.  Acquired EGFR C797S mediates resistance to AZD9291 in advanced non-small cell lung cancer harboring EGFR T790M , 2015, Nature Medicine.

[10]  Masanori Kato,et al.  Abstract C111: In vitro characterization of TAS-121, a novel, highly potent, and mutant-specific EGFR-TKI. , 2013 .

[11]  Chun-Ming Tsai,et al.  Phase III study of afatinib or cisplatin plus pemetrexed in patients with metastatic lung adenocarcinoma with EGFR mutations. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[12]  William Pao,et al.  Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease. , 2013, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[13]  William Pao,et al.  Analysis of Tumor Specimens at the Time of Acquired Resistance to EGFR-TKI Therapy in 155 Patients with EGFR-Mutant Lung Cancers , 2013, Clinical Cancer Research.

[14]  A. Zlotnik,et al.  The chemokine superfamily revisited. , 2012, Immunity.

[15]  E. Felip,et al.  Erlotinib versus standard chemotherapy as first-line treatment for European patients with advanced EGFR mutation-positive non-small-cell lung cancer (EURTAC): a multicentre, open-label, randomised phase 3 trial. , 2012, The Lancet. Oncology.

[16]  A. Gemma,et al.  F1000 highlights , 2010 .

[17]  T. Mok,et al.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma. , 2009, The New England journal of medicine.

[18]  P. Jänne,et al.  The impact of human EGFR kinase domain mutations on lung tumorigenesis and in vivo sensitivity to EGFR-targeted therapies. , 2006, Cancer cell.

[19]  J. Minna,et al.  Clinical and biological features associated with epidermal growth factor receptor gene mutations in lung cancers. , 2006, Journal of the National Cancer Institute.

[20]  Patricia L. Harris,et al.  Activating mutations in the epidermal growth factor receptor underlying responsiveness of non-small-cell lung cancer to gefitinib. , 2004, The New England journal of medicine.

[21]  Jie Yang,et al.  Overview of current systemic management of EGFR-mutant NSCLC , 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

[22]  L. Tanoue.  Gefitinib or Chemotherapy for Non–Small-Cell Lung Cancer with Mutated EGFR , 2011 .